AFMD News and Press, Affimed N.V. From 07/01/21

AFM13 monotherapy: Reported positive outcome from the preplanned interim analysis for the registration-directed trial in PTCL; enrollment expected to be completed in the first half of 2022. AFM13 combination with NK cells: Announced 100% objective response rate in the first four respo...

HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2021 results on Thursday, July 1, 2021, and...

HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board...

Heidelberg, Germany, May 26, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual...

Heidelberg, Germany, May 20, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the “Annual Meeting&#...

This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As clinical data continues to strengthen, Immutep is seemingly well situated for pot...

Shares of Affimed (NASDAQ: AFMD) have been soaring on the back of positive clinical trial results for an experimental cancer therapy that could be worth billions. The stock has already gained around 61% this year, but some biotech investors think it could climb much higher. Can ...

AFM13 in combination with natural killer (NK) cells demonstrated improved tumor recognition and enhanced tumor cell killing in vitro and in vivo. Preclinical data from this publication supported the Investigational New Drug (IND) application for the ongoing Phase I clinical study ...

Affimed N.V. (NASDAQ:AFMD) traded today at a new 52-week high of $11.30. Approximately 9.6 million shares have changed hands today, as compared to an average 30-day volume of 5.3 million shares. Affimed N.V. share prices have moved between a 52-week high of $11.30 and a 52-week low of $1...

In an increasingly saturated landscape of immune oncology companies, Affimed presents a new solution through innate NK cell therapies designed to fight relapsed cancers. Affimed’s core technology has garnered corporate interest in the sector, leading to immune oncology partners...